Online citations, reference lists, and bibliographies.
← Back to Search

Expression Of Calretinin By Breast Carcinoma And The Potential For Misdiagnosis Of Mesothelioma

G. Powell, Heather Roche, W. Roche
Published 2011 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Powell G, Roche H & Roche W R 
(2011) Histopathology59, 950–956
This paper references
10.1016/j.ejim.2007.09.014
Prognostic significance of pleural fluid data in patients with malignant effusion.
S. Bielsa (2008)
10.1097/00000478-200302000-00002
Expression of Calretinin, Thrombomodulin, Keratin 5, and Mesothelin in Lung Carcinomas of Different Types: An Immunohistochemical Analysis of 596 Tumors in Comparison With Epithelioid Mesotheliomas of the Pleura
M. Miettinen (2003)
10.1053/S0046-8177(03)00339-3
Calretinin expression in human normal and neoplastic tissues: a tissue microarray analysis on 5233 tissue samples.
A. Lugli (2003)
10.1002/path.1916
Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation
E. Rakha (2006)
10.1073/pnas.0932692100
Repeated observation of breast tumor subtypes in independent gene expression data sets
T. Sørlie (2003)
10.1038/modpathol.3800259
Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma
Albert Y Chu (2005)
10.1097/00000478-199609000-00001
Calretinin: a novel immunocytochemical marker for mesothelioma.
C. Doglioni (1996)
10.1038/35021093
Molecular portraits of human breast tumours
C. Perou (2000)
10.1038/modpathol.3880483
Expression of Cytokeratin 5/6 in Epithelial Neoplasms: An Immunohistochemical Study of 509 Cases
P. Chu (2002)
10.1038/modpathol.3800471
The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study
N. Ordóñez (2006)
10.1038/modpathol.3800528
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
C. Livasy (2006)
10.1002/cncr.22477
Novel marker D2‐40, combined with calretinin, CEA, and TTF‐1
T. Mimura (2007)
10.1016/J.CRAD.2004.05.001
Patterns of metastatic breast carcinoma: influence of tumour histological grade.
G. Porter (2004)
10.1016/J.CLON.2007.10.002
The influence of basal phenotype on the metastatic pattern of breast cancer.
A. A. Luck (2008)
10.1158/1078-0432.CCR-06-1109
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
L. Carey (2007)
10.1043/1543-2165(2008)132[397:AOITTD]2.0.CO;2
Application of immunohistochemistry to the diagnosis of malignant mesothelioma.
A. Marchevsky (2008)
10.1016/j.ejcts.2007.09.044
Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
P. Borasio (2008)
10.1002/path.1559
Expression of luminal and basal cytokeratins in human breast carcinoma
D. A. Abd El-Rehim (2004)
10.1111/j.1440-1827.2007.02080.x
Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma
K. Kushitani (2007)
10.1111/j.1365-2559.2006.02453.x
Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast
L. Fulford (2006)
10.1097/00000478-200308000-00001
The Immunohistochemical Diagnosis of Mesothelioma: A Comparative Study of Epithelioid Mesothelioma and Lung Adenocarcinoma
N. Ordóñez (2003)
10.1038/modpathol.3880018
Value of the Mesothelium-Associated Antibodies Thrombomodulin, Cytokeratin 5/6, Calretinin, and CD44H in Distinguishing Epithelioid Pleural Mesothelioma from Adenocarcinoma Metastatic to the Pleura
P. Cury (2000)
Diagnosis of diffuse malignant mesothelioma: experience of a US/Canadian Mesothelioma Panel.
W. Mccaughey (1991)
10.1073/pnas.191367098
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T. Sørlie (2001)
10.1111/j.1365-2559.2008.03178.x
Problems in mesothelioma diagnosis
Bruce Addis (2009)
10.1016/J.HUMPATH.2004.11.011
The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors.
H. Cathro (2005)
10.1016/J.HUMPATH.2003.11.013
The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study.
N. Ordóñez (2004)
10.1136/jcp.2005.033043
Basal-like breast carcinomas: clinical outcome and response to chemotherapy
S. Banerjee (2006)
10.1158/1078-0432.CCR-04-0220
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
T. Nielsen (2004)
10.1046/j.1365-2559.2001.01092.x
Immunohistochemistry and the diagnosis of malignant mesothelioma
J. King (2001)
Programmes and The Royal College of Pathologists, Pathology reporting of breast disease, NHSBSP Publication no
NHS Cancer Screenin (2005)
10.1002/ijc.21004
High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses
D. A. Abd El-Rehim (2005)
10.1158/1078-0432.CCR-04-2421
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
R. Rouzier (2005)
10.1136/jcp.55.9.662
Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies
A. S. Abutaily (2002)
10.1023/B:BREA.0000010706.24181.b6
Malignant Pleural and Pericardial Effusion in Invasive Breast Cancer: Impact of the Site of the Primary Tumor
W. Pokieser (2004)
10.1016/S0002-9440(10)64476-8
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome.
M. van de Rijn (2002)
10.1046/j.1365-2559.1998.00349.x
E‐cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma
Leers (1998)
10.1053/HUPA.2001.24329
Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
C. Comin (2001)
NHS Cancer Screening Programmes and The Royal College of Pathologists, Pathology reporting of breast disease, NHSBSP Publication no. 58
(2005)
10.1097/00000478-200101000-00004
Immunohistochemical Panels For Differentiating Epithelial Malignant Mesothelioma From Lung Adenocarcinoma: A Study With Logistic Regression Analysis
R. Carella (2001)
10.1186/bcr1636
Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival
L. Fulford (2006)
Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.
N. Ordóñez (1998)
10.1097/00000478-199810000-00006
Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
N. Ordóñez (1998)



This paper is referenced by
Chirurgische Aspekte des malignen Pleuramesothelioms
Aus Sicht der Pathologie (2013)
10.4103/0377-4929.200046
Calretinin expression as a reliable prognostic marker in different molecular subtypes of breast carcinoma
M. Farrag (2017)
10.1002/1878-0261.12749
Upregulation of mesothelial genes in ovarian carcinoma cells is associated with an unfavorable clinical outcome and the promotion of cancer cell adhesion
Kaire Ojasalu (2020)
10.23958/ijirms/vol04-i01/550
Expression of Mesothelial Marker Calretinin in Breast Cancer
Kalathingal Kamarunisha Aboobacker (2019)
10.1097/PAI.0b013e31829b6fbd
Value of Calretinin Immunostaining in Diagnostic Pathology: A Review and Update
N. Ordóñez (2014)
10.18203/2320-6012.ijrms20201349
Calretinin expression in molecular subtypes of invasive carcinoma breast
Suryagayathri Venugopal (2020)
10.1136/jclinpath-2012-201303
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers
D. Henderson (2013)
10.1007/s00428-017-2149-4
Expression of calretinin in high-grade hormone receptor-negative invasive breast carcinomas: correlation with histological and molecular subtypes
Donata Micello (2017)
10.1016/j.humpath.2012.05.014
Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update.
N. Ordóñez (2013)
10.1186/2162-3619-3-12
Expression and diagnostic values of calretinin and CK5/6 in cholangiocarcinoma
L. Zhang (2014)
10.1186/s12957-015-0491-z
Breast cancer or metastasis? An unusual case of metastatic malignant pleural mesothelioma to the breast
M. Framarino-Dei-Malatesta (2015)
10.1016/j.prp.2016.07.010
Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach.
V. Ascoli (2016)
10.21608/zumj.2016.4649
CLINICOPATHOLOGIC CORRELATION OF CALRETININ EXPRESSION IN BREAST CANCER
Mayada Saad Farrag (2016)
10.5858/arpa.2014-0092-RA
Utility of immunohistochemistry in the diagnosis of pleuropulmonary and mediastinal cancers: a review and update.
K. Zhang (2014)
10.1016/j.humpath.2014.03.006
Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study.
N. Ordóñez (2014)
The Importance of Investigating Tumor Biology and Biomarkers in Pleural Effusions
Begüm Görgülü (2018)
10.1155/2015/298523
Malignant Mesothelioma Mimicking Invasive Mammary Carcinoma in a Male Breast
M. Desouki (2015)
10.1007/978-1-4939-1578-1_18
Pleuropulmonary and Mediastinal Neoplasms
K. Zhang (2015)
10.1007/s00104-012-2431-6
Chirurgische Aspekte des malignen Pleuramesothelioms
A. Fisseler-Eckhoff (2012)
10.5858/arpa.2017-0124-RA
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
A. Husain (2018)
10.3978/j.issn.2072-1439.2013.11.28
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
10.1136/jclinpath-2012-201020
CD24: a potential new marker in differentiating malignant mesothelioma from pulmonary adenocarcinoma
D. Pinato (2012)
Cutaneous metastases from breast carcinoma: calretinin expression and estrogen, progesterone and Her2/neu status of the metastases, compared to primary cutaneous apocrine tumors.
A. Fernandez-Flores (2013)
Cutaneous metastases from breast carcinoma : calretinin expression and estrogen , progesterone and Her 2 / neu status of the metastases , compared to primary cutaneous apocrine tumors
A. Fernandez (2013)
10.4103/EGJP.EGJP_23_19
Hyaluronan expression as a reliable tumor and stromal prognostic marker in different molecular subtypes of breast carcinoma
M. Farrag (2019)
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma
Aliya N. Husain (2017)
10.1016/j.pathol.2016.08.003
Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma.
B. Thapa (2016)
10.1016/j.humpath.2013.07.021
Calretinin expression in high-grade invasive ductal carcinoma of the breast is associated with basal-like subtype and unfavorable prognosis.
Ross Taliano (2013)
Semantic Scholar Logo Some data provided by SemanticScholar